James Spalding
Overview
Explore the profile of James Spalding including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
808
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pandya B, Burns L, Wang T, Xie B, Touya M, Spalding J, et al.
Transplant Cell Ther
. 2024 Apr;
30(7):683.e1-683.e13.
PMID: 38663769
Allogeneic hematopoietic cell transplantation (alloHCT) is used to treat patients with acute myeloid leukemia (AML) with internal tandem duplication of the FMS-like tyrosine kinase 3 gene (FLT3-ITD). However, the effect...
2.
Divakaran S, Singh A, Defilippis E, Churchill T, Cuddy S, Ge Y, et al.
J Nucl Cardiol
. 2019 Nov;
28(5):1988-1997.
PMID: 31741326
Background: An upcoming national mandate will require consultation of appropriate use criteria (AUC) through a clinical decision support mechanism (CDSM) for advanced imaging. We aimed to evaluate our current ability...
3.
Webb B, Ferraro J, Rea S, Kaufusi S, Goodman B, Spalding J
Open Forum Infect Dis
. 2018 Aug;
5(8):ofy187.
PMID: 30151412
Background: A better understanding of the epidemiology and clinical features of invasive fungal infection (IFI) is integral to improving outcomes. We describe a novel case-finding methodology, reporting incidence, clinical features,...
4.
Bunniran S, Lee E, Kamble P, Suehs B, Franks B, Schwartz J, et al.
J Med Econ
. 2018 Jul;
21(11):1067-1074.
PMID: 30032686
Aims: Switching drug manufacturers in transplant patients may require an increased intensity of therapeutic monitoring, leading to additional healthcare visits, associated laboratory tests, and perhaps hospitalizations. As real-world studies examining...
5.
Webb B, Harrington R, Schwartz J, Kammerer J, Spalding J, Lee E, et al.
Transpl Infect Dis
. 2018 Jul;
20(5):e12961.
PMID: 29975816
Background: CMV infection (CMV-I) remains an important complication of hematopoietic stem cell transplantation (HSCT). Methods: This was a retrospective, single-center cohort study in HSCT recipients. Primary outcomes were adjusted cost...
6.
Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, et al.
Adv Ther
. 2016 Dec;
34(1):207-220.
PMID: 27913989
Introduction: Invasive aspergillosis (IA) is associated with a significant clinical and economic burden. The phase III SECURE trial demonstrated non-inferiority in clinical efficacy between isavuconazole and voriconazole. No studies have...
7.
Andes D, Azie N, Yang H, Harrington R, Kelley C, Tan R, et al.
Antimicrob Agents Chemother
. 2016 Mar;
60(6):3398-406.
PMID: 27001815
The majority of hospitalized patients receiving mold-active triazoles are at risk of drug-drug interactions (DDIs). Efforts are needed to increase awareness of DDIs that pose a serious risk of adverse...
8.
Hudgens S, Spalding J, Chaudhari P
Clin Ther
. 2016 Mar;
38(5):1141-50.
PMID: 26992664
Purpose: The objective of this study was to develop and validate clinician and patient measures of satisfaction for pharmacologic stress agents (PSAs) used in single-photon emission computed tomography myocardial perfusion...
9.
Horn D, Goff D, Khandelwal N, Spalding J, Azie N, Shi F, et al.
J Med Econ
. 2016 Mar;
19(7):728-34.
PMID: 26960060
Objective: In the phase III SECURE trial, isavuconazole was non-inferior to voriconazole for all-cause mortality for the primary treatment of invasive mold disease (IMD) caused by Aspergillus spp. and other...
10.
Hudgens S, Breeze J, Spalding J
J Med Econ
. 2013 Apr;
16(6):828-34.
PMID: 23614479
Objective: The objective of this study was to compare clinician and patient measures of satisfaction with two pharmacological stress agents (PSA), regadenoson and dipyridamole, used in Single Photon Emission Computed...